EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 11

Ensembl ID : ENSVPAG00000012535
Gene Symbol: SCN11A
1 Cross references
96 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSVPAG00000003468
Gene Symbol: SCN2A
1 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSVPAG00000003464
Gene Symbol: SCN3A
1 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSVPAG00000007813
Gene Symbol: SCN7A
1 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSVPAG00000007705
Gene Symbol: SCN8A
1 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSVPAG00000007808
Gene Symbol: SCN9A
1 Cross references
110 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSVPAG00000005329
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSVPAG00000002383
Gene Symbol: SLC18A2
1 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSVPAG00000000079
Gene Symbol: SLC22A8
1 Cross references
310 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSVPAG00000011461
Gene Symbol: SLC6A1
1 Cross references
276 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSVPAG00000003570
Gene Symbol: SLC6A4
1 Cross references
204 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSVPAG00000007157
Gene Symbol: SSTR2
1 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).